35th week of 2014 patent applcation highlights part 56 |
Patent application number | Title | Published |
20140243202 | STABLE, CONCENTRATED HERBICIDAL COMPOSITIONS - A liquid herbicidal composition is provided, comprising:
| 2014-08-28 |
20140243203 | GENE SWITCH COMPOSITIONS AND METHODS OF USE - Compositions and methods relating to the use of sulfonylurea-mediated control of gene expression are provided. Compositions include sulfonylurea responsive chemical switches wherein the gene expression is regulated by a sulfonylurea compound. Compositions also include polynucleotides encoding the polypeptides as well as constructs, vectors, prokaryotic and eukaryotic cells, and eukaryotic organisms including plants and seeds comprising the polynucleotide, and/or produced by the methods. Also provided are methods to regulate expression of a polynucleotide of interest in a cell or organism, and methods to modify a genome, including in a plant or plant cell. | 2014-08-28 |
20140243204 | METHODS OF AND APPARATUS FOR EXTRACTING 3-METHYL-2H-FURO[2,3-C]PYRAN-2-ONE - A method for extracting the compound 3-methyl-2H-furo[2,3-c]pyran-2-one from smoke, the method comprising pyrolysis of cellulose or any biomass within a combustion chamber, directing the smoke into a scrubbing apparatus incorporating a spiral condenser tube extending along the chamber and having a number of mist spray units spaced along the entire spiral condenser tube, collecting smoke water thus formed and passing it to a cooling chamber and then to preparation for storage or despatch. | 2014-08-28 |
20140243205 | VERY EFFICIENT HEAT EXCHANGER FOR CRYOGEN FREE MRI MAGNET - A heat exchanger ( | 2014-08-28 |
20140243206 | CRYOGENIC HEAT SINK FOR GAS COOLED SUPERCONDUCTING POWER DEVICES - A heat sink and method for gaseous cooling of superconducting power devices. Heat sink is formed of a solid material of high thermal conductivity and attached to the area needed to be cooled. Two channels are connected to the heat sink to allow an inlet and an outlet for cryogenic gaseous coolant. Inside the hollow heat sink are fins to increase metal surface in contact with the coolant. The coolant enters through the inlet tube, passes through the finned area inside the heat sink and exits through the outlet tube. | 2014-08-28 |
20140243207 | Superconducting flat tape cable magnet - A method for winding a coil magnet with the stacked tape cables, and a coil so wound. The winding process is controlled and various shape coils can be wound by twisting about the longitudinal axis of the cable and bending following the easy bend direction during winding, so that sharp local bending can be obtained by adjusting the twist pitch. Stack-tape cable is twisted while being wound, instead of being twisted in a straight configuration and then wound. In certain embodiments, the straight length should be half of the cable twist-pitch or a multiple of it. | 2014-08-28 |
20140243208 | COMPOSITIONS AND METHODS FOR SELECTING APTAMERS - The invention encompasses compositions and methods for selecting aptamers. | 2014-08-28 |
20140243209 | METHOD FOR DETECTING PROTEIN THAT INTERACTS WITH TARGET SUBSTANCE - The present invention provides a method for detecting an interaction, which method can solve not only the problem of false negatives but also the problem of false positives. This method is a method for detecting a protein(s) that interact(s) with a target substance(s), the method comprising repeating a (1) transcription step, (2) assignment step, (3) selection step, and (4) amplification step, wherein: (a) in each of a plurality of times of preparation of a cDNA library among the initial preparation of a cDNA library and the round(s) of preparation of a cDNA library in the later amplification step(s), the cDNA library is prepared using a primer(s) having a sequence(s) specific to the time of preparation; (b) the cDNA libraries prepared using the primers having sequences specific to the times of preparation are mixed, and sequences in the cDNA library mixture are determined; (c) the determined sequences are subjected to measurement of the number(s) of molecules encoding the same candidate protein(s) for each time of preparation based on the sequence(s) specific to the time of preparation; and (d) a candidate protein(s) encoded by a molecule(s) that significantly increase(s) as the preparation rounds proceed is/are detected as the protein(s) that interact(s) with the target substance(s). | 2014-08-28 |
20140243210 | PURIFICATION OF IMMUNOGLOBULINS USING AFFINITY CHROMATOGRAPHY AND PEPTIDE LIGANDS - An immunoglobulin binding peptide having the general formula, from amino terminus to carboxy terminus, of Z—R | 2014-08-28 |
20140243211 | BLOOD BIOMARKERS FOR SUICIDALITY - Biomarkers and methods for screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side-effect of an antidepressant are disclosed. | 2014-08-28 |
20140243212 | MATERNAL PLASMA TRANSCRIPTOME ANALYSIS BY MASSIVELY PARALLEL RNA SEQUENCING - Methods are provided for diagnosing pregnancy-associated disorders, determining allelic ratios, determining maternal or fetal contributions to circulating transcripts, and/or identifying maternal or fetal markers using a sample from a pregnant female subject. Also provided is use of a gene for diagnosing a pregnancy-associated disorder in a pregnant female subject. | 2014-08-28 |
20140243213 | Analysing Sequencing Bias - The present invention relates to methods for determining the sequence bias of a sequencing technique. Furthermore, the invention relates to methods to reduce or enhance sequence bias during sequencing of nucleic acids via techniques involving adaptor ligations. Specifically the method relates to use of a degenerate RNA sequence to analyse sequence bias when generating small RNA libraries, and to the use of modified adaptors for cloning of small RNAs with degenerate or specific sequences to reduce or enhance sequencing bias, as well as various nucleic acid molecules relating thereto or derived therefrom. | 2014-08-28 |
20140243214 | FET ARRAY SUBSTRATE, ANALYSIS SYSTEM AND METHOD - In an FET configuration having a channel with a small thickness, transistor characteristics vary for different FETs in the same array, and therefore when the same gate voltage is applied, the sensitivities of DNA detection may be insufficient. To this end, the change in the channel current when DNA passes through the nanopore is detected while applying an optimum gate voltage for each nanopore FET to attain a predetermined channel current value to a plurality of nanopore FETs disposed on the same substrate, and four types of bases constituting DNA are distinguished. | 2014-08-28 |
20140243215 | METHOD FOR DIAGNOSING RENAL DISEASES OR PREDISPOSITIONS - The invention provides a method of diagnosing a disease or a predisposition to contract a disease by assaying for mutations of uromodulin (UMOD) within a test subject or patient. The presence of a mutation in the UMOD supports a diagnosis of a disease or a predisposition to contract a disease within the patient. | 2014-08-28 |
20140243216 | METHODS FOR SEPARATING NUCLEIC ACIDS BY SIZE - The present invention pertains to a method for isolating nucleic acids by size from a sample comprising nucleic acids of different sizes using an anion exchange matrix, wherein nucleic acids of a preselected size or a preselected size range are isolated by varying the pH value during elution and/or binding. | 2014-08-28 |
20140243217 | METHODS AND COMPOSITIONS FOR DETECTING PLANT EXPOSURE TO PLANT PATHOGENS - The present disclosure provides methods an compositions for the detection of plant exposure to plant pathogens. The methods relate to determining the identity of peptides isolated from the surface of plant starch granules. | 2014-08-28 |
20140243218 | COMPOSITION FOR DIAGNOSING OVARIAN CANCER METASTASIS USING CPG METHYLATION STATUS OF GENE PROMOTER AND USE THEREOF - The present invention relates to a composition, a kit and a method for diagnosing ovarian cancer metastasis or predicting the risk of metastasis by detecting methylation levels at CpG sites of one or more gene promoters selected from the group consisting of AGR2 (anterior gradient 2), CA9 (carbonic adj anhydrase 9), GABRP (gamma-aminobutyric acid receptor pi subunit), IFITM1 (interferon-induced transmembrane 1) and MUC13 (mucin 13). | 2014-08-28 |
20140243219 | METHODS AND SIGNATURES FOR OROPHARYNGEAL CANCER PROGNOSIS - Methods for determining the prognosis of a subject with oropharyngeal squamous cell carcinoma are described, as well as miRNAs and panels of prognostic miRNAs that are used in the methods. | 2014-08-28 |
20140243220 | Metaproteomic Method to Identify Secreted Pattern Recognition Molecules and Adhesive Antimicrobial Factors for Detection of Microbial Agents Eliciting Inflammation in the Human Host - Described herein are methods for analyzing complex host-microbial mixtures. The disclosed methods may be used to diagnosis or prognose in a subject an inflammatory disease, which is caused by or contributed to by microbes. | 2014-08-28 |
20140243221 | METHOD FOR IDENTIFYING CELLS BASED ON DNA REPLICATION DOMAIN TIMING PROFILES - Methods for identifying and/or distinguishing a homogeneous population of cells based on their replication domain timing profile using high resolution genomic arrays or sequencing procedures are provided. These methods may be used to compare the replication timing profile for a population of cells to another replication timing profile(s), a replication timing fingerprint, and/or one or more informative segments of a replication timing fingerprint, which may be simultaneously or previously determined and/or contained in a database, to determine whether there is a match between them. Based on such information, the identity of the population of cells may be determined, or the identity of the population of cells may be distinguished from other populations of cells or cell types. Methods for determining a replication timing fingerprint for particular cell types are also provided. | 2014-08-28 |
20140243222 | MULTI-SPOT METAL-CAPPED NANOSTRUCTURE ARRAY NUCLEIC ACID CHIP FOR DIAGNOSING OF CORNEAL DYSTROPHY AND PREPARATION METHOD THEREOF PRODUCING SAME - A multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing corneal dystrophy, and more particularly to a multi-spot metal-capped nanostructure array nucleic acid chip capable of employing LSPR (localized surface plasmon resonance) optical properties, a preparation method thereof, and a multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing BIGH3 gene mutations, which can diagnose various corneal dystrophies. The metal-capped nanostructure array nucleic acid chip can be combined with analysis devices, including a light source, a detector, a spectrophotometer and a computer, to provide an LSPR optical property-based optical biosensor, and the use of the multi-spot metal-capped nanostructure array nucleic acid chip for diagnosing BIGH3 gene mutations allows the simultaneous diagnosis of various corneal dystrophies that are genetic ocular diseases. | 2014-08-28 |
20140243223 | ULTRA-SENSITIVE DETECTION OF MOLECULES ON SINGLE MOLECULE ARRAYS - The present invention relates to systems and methods for detecting analyte molecules or particles in a fluid sample and in some cases, determining a measure of the concentration of the molecules or particles in the fluid sample. Methods of the present invention may comprise immobilizing a plurality of analyte molecules or particles to form a plurality of complexes, releasing at least a portion of some of the plurality of complexes, determining at least a portion of the plurality of complexes released, and determining a measure of the concentration of the analyte molecules or particles in a fluid sample. | 2014-08-28 |
20140243224 | GEL PATTERNED SURFACES - Provided is an array including a solid support having a surface, the surface having a plurality of wells, the wells containing a gel material, the wells being separated from each other by interstitial regions on the surface, the interstitial regions segregating the gel material in each of the wells from the gel material in other wells of the plurality; and a library of target nucleic acids in the gel material, wherein the gel material in each of the wells comprises a single species of the target nucleic acids of the library. Methods for making and using the array are also provided. | 2014-08-28 |
20140243225 | Multiplex Compositions And Methods For Quantification Of Human Nuclear DNA And Human Male DNA And Detection of PCR Inhibitors - The invention relates to a method for simultaneous quantification of human nuclear DNA and human male DNA in a biological sample while also detecting the presence of PCR inhibitors in a single reaction. The multiplex quantification method also provides a ratio of human nuclear and male DNA present in a biological sample. Such sample characterization is useful for achieving efficient and accurate results in downstream molecular techniques such as genotyping. | 2014-08-28 |
20140243226 | SIGNATURES OF RADIATION RESPONSE - The present invention relates, in general, to gene expression profiles, and in particular, to a peripheral blood gene expression profile of an environmental exposure, ionizing radiation. The invention further relates to methods of screening patients for radiation exposure based on gene expression profiling and to kits suitable for use in such methods. | 2014-08-28 |
20140243227 | CULTURE MEDIA FOR STEM CELLS - Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine. | 2014-08-28 |
20140243228 | HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES - System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity. | 2014-08-28 |
20140243229 | METHODS AND PRODUCTS RELATED TO GENOTYPING AND DNA ANALYSIS - The invention encompasses methods and products related to genotyping. The method of genotyping of the invention is based on the use of single nucleotide polymorphisms (SNPs) to perform high throughput genome scans. The high throughput method can be performed by hybridizing SNP allele-specific oligonucleotides and a reduced complexity genome (RCG). The invention also relates to methods of preparing the SNP specific oligonucleotides and RCGs, methods of fingerprinting, determining allele frequency for a SNP, characterizing tumors, generating a genomic classification code for a genome, identifying previously unknown SNPs, and related compositions and kits. | 2014-08-28 |
20140243230 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF KIDNEY TUMORS - The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 2014-08-28 |
20140243231 | METHODS AND COMPOSITIONS FOR THE EFFICIENT REUSE OF MULTIPLY DYED PARTICLES - Provided herein are compositions and methods for reuse and/or recycling of internally dyed particles useful for multiplex assays of target analytes. | 2014-08-28 |
20140243232 | NUCLEIC ACID COMPLEXITY REDUCTION - In some embodiments, the present teachings provide compositions, systems, methods and kits for reducing the complexity of nucleotide sequences in a nucleic acid sample comprising the steps: hybridizing a plurality of polynucleotide constructs to at least one blocker oligonucleotide and to at least one capture oligonucleotide, wherein the plurality of polynucleotide constructs include a plurality of polynucleotides each joined to at least one nucleic acid adaptor, wherein the at least one nucleic acid adaptor can hybridize to the at least one blocker oligonucleotide, and wherein the at least one capture oligonucleotide can hybridize to at least a portion of target polynucleotides that are a sub-population of the plurality of polynucleotides, so as to produce a capture duplex. | 2014-08-28 |
20140243233 | METHODS FOR MEASURING HDL SUBPOPULATIONS - This invention provides a capture/detection antibody-based method for measuring the amount of a high density lipoprotein (HDL) subpopulation present in a sample, wherein each particle of the HDL subpopulation being measured is characterized by the presence of a plurality of defined protein epitopes. This invention also provides related analytical and diagnostic methods, as well as kits for performing same. | 2014-08-28 |
20140243234 | NUCLEIC ACID COMPOSITIONS, METHODS AND KITS FOR RAPID PAIRING OF AFFINITY AGENTS - The present inventions relate to the selection and production of specific proteins or peptides with desired properties. The inventions relate to the agents and methods of identifying select peptides or proteins with specific binding properties or greater enzymatic performance from vast numbers of variants. | 2014-08-28 |
20140243235 | PERIPHERAL NEUROPATHY DIAGNOSIS - Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject. | 2014-08-28 |
20140243236 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays. | 2014-08-28 |
20140243237 | METHOD FOR EVALUATING DRUG SENSITIVITY AND DISEASE VULNERABILITY BY ANALYZING CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN GENE - The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual. | 2014-08-28 |
20140243238 | METHODS OF CO-DETECTING MRNA AND SMALL NON-CODING RNA - Disclosed herein are methods of co-detecting presence of target messenger RNA (mRNA) and small non-coding RNA (for example, miRNA) in a sample. The disclosed methods can be used to simultaneously detect mRNA and small non-coding RNA in a single assay (for example in the same reaction or the same well of a multi-well assay). The methods can include contacting a sample with a plurality of nuclease protection probes including at least one probe which specifically binds to a target mRNA and at least one probe which specifically binds to a target small non-coding RNA, contacting the sample with a nuclease specific for single-stranded nucleic acids, and detecting the NPP, for example on a microarray. | 2014-08-28 |
20140243239 | MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF - This invention is directed to a multi-analyte column comprising two or more layers with a first solid support having specific binding affinity for kinases and a second solid support having non-specific binding affinity for kinases. Methods are also provided, including methods of detecting low abundance kinases, predicting resistance to chemotherapy, determining cancer prognosis, and improving the effectiveness of a treatment regimen. | 2014-08-28 |
20140243240 | microRNA EXPRESSION PROFILING OF THYROID CANCER - Methods of screening an individual for thyroid cancer or a potential for developing thyroid cancer, and for diagnosing thyroid cancer or a potential for developing thyroid cancer in an individual subject in need thereof includes: determining expression levels of at least one miRNA selected from a first group of specific miRNAs; compare the expression levels of the at least one miRNA from the first group with the expression levels of the corresponding miRNA established for a control individual not having thyroid cancer or nodular hyperplasia, and identifying differences in the miRNA expression levels between the at least one sample from said individual subject and miRNA expression levels established for a control individual not having thyroid cancer or nodular hyperplasia. Methods of treating an individual subject having thyroid cancer and/or a potential for developing thyroid cancer using these procedures in selecting the most appropriate method of treatment for the particular stage and/or type of thyroid cancer. | 2014-08-28 |
20140243241 | METHOD FOR MEASURING BETA-LACTAM ANTIBIOTICS - The present invention relates to methods for determining the concentration of a free beta-lactam antibiotic in a biological sample. In particular, the present invention relates to methods for measuring a free beta-lactam antibiotic in a biological sample, comprising the steps of: (a) providing at least one class C beta-lactamase, a functional fragment or variant thereof; (b) providing at least one biological sample; (c) contacting said at least one class C beta-lactamase with said at least one biological sample; and (d) determining the concentration of said free beta-lactam antibiotic in said at least one biological sample. | 2014-08-28 |
20140243242 | COMPOSITIONS AND METHODS FOR CO-AMPLIFYING SUBSEQUENCES OF A NUCLEIC ACID FRAGMENT SEQUENCE - The present invention is related to genomic nucleotide sequencing. In particular, the invention describes a single reaction method to co-amplify multiple subsequences of a nucleic acid fragment sequence (i.e., for example, at least two read pairs from a single library insert sequence). Nucleic acid fragment sequences may include, but are not limited to, localizing library insert sequences and/or unique read pair sequences in specific orientations on a single emulsion polymerase chain reaction bead. Methods may include, but are not limited to, annealing, melting, digesting, and/or reannealing high throughput sequencing primers to high throughput sequencing primer binding sites. The compositions and methods disclosed herein contemplate sequencing complex genomes, amplified genomic regions, as well as detecting chromosomal structural rearrangements that are compatible with massively parallel high throughput sequencing platforms as well as ion semiconductor matching sequencing platforms (i.e., for example, Ion Torrent platforms). | 2014-08-28 |
20140243243 | DEVICE AND METHOD FOR CELL-EXCLUSION PATTERNING - This disclosure relates to devices and methods for cell-exclusion patterning. Specifically, this disclosure provides a device and method to exclude cells in selected areas during cell seeding and create cell-free arrays that can be used for cell migration and related studies and assays. | 2014-08-28 |
20140243244 | MICRO-BUBBLE PLATE FOR PATTERNING BIOLOGICAL AND NON-BIOLOGICAL MATERIALS - Systems and methods are provided for patterning biological and non-biological material at specific sites on a plate, as well as growing three dimensional structures. Preferred embodiments comprise a plate with regions that will trap gas, usually in the form of bubbles, when the plate is submerged in liquid. Other embodiment of the present invention include a method for placing materials on the plate at pre-determined locations through the use of trapped gas to prevent materials from collecting at unwanted regions. The plate has great utility for plating cells and tissues at specific sites, such as on an array. The disclosed method can also be used to coat the surface of a plate with coatings at specific locations for patterned coating applications and to build up materials to produce three dimensional structures, including micromechanical structures—where the structures may be formed from living or non-living material, tissue or non-tissue, organic or inorganic, and the like. | 2014-08-28 |
20140243245 | Control of Particulate Entrainment by Fluids - An aqueous slurry composition for use in industries such as petroleum and pipeline industries that includes: a particulate, an aqueous carrier fluid, a chemical compound that renders the particulate surface hydrophobic, and a small amount of an oil. The slurry is produced by rendering the surface of the particulate hydrophobic during or before the making of the slurry. The addition of the oil greatly enhances the aggregation potential of the hydrophobically modified particulates once placed in the well bore. | 2014-08-28 |
20140243246 | HYDRAULIC FRACTURE COMPOSITION AND METHOD - A method for improving the performance of fracturing processes in oil production fields may rely on polymer coated particles carried in the fracturing fluid. The particles may include heavy substrates, such as sand, ceramic sand, or the like coated with polymers selected to absorb water, increasing the area and volume to travel more readily with the flow of fluid without settling out, or allowing the substrate to settle out. Ultimately, the substrate may become lodged in the fissures formed by the pressure or hydraulic fracturing, resulting in propping open of the fissures for improved productivity. | 2014-08-28 |
20140243247 | ASHLESS OR REDUCED ASH QUATERNARY DETERGENTS - A composition of an oil-soluble ionic detergent that does not contribute metal ions to the composition, and which comprises a quaternary non-metallic pnictogen cation and an organic anion having at least one hydrocarbyl group of sufficient length to impart oil solubility to the detergent, the detergent having a total base number (TBN) to total acid number (TAN) ratio of at least 2:1 imparts ash-free basicity to a lubricant composition. | 2014-08-28 |
20140243248 | Biological method for preventing rancidity, spoilage and instability of hydrocarbon and water emulsions and also increase the lubricity of the same - A method for preventing degradation of physical and chemical properties, and for increasing lubricity, of a hydrocarbon and water emulsion, comprising adding to the emulsion an effective amount of at least one copper salt of a carboxylic acid for enabling at least one bacterium species from | 2014-08-28 |
20140243249 | METAL STRIPPING ADDITIVE, COMPOSITION CONTAINING THE SAME, AND METHOD FOR STRIPPING METAL BY USING THE COMPOSITION - The present invention provides a metal stripping additive, composition containing the same, and method for stripping metal by using the composition. The metal stripping additive comprises a phosphate, a carbonate, and a component selected from at least one of citric acid or a derivative thereof, oxalate or a derivative thereof, malate or a derivative thereof. The metal stripping additive is used with nitric acid as the metal stripping composition of the present invention. The present method has advantages of being capable of stripping various metals, low corrosion, low toxicity, and being applicable under ambient temperature. | 2014-08-28 |
20140243250 | POLISHING SLURRY FOR COBALT REMOVAL - Provided herein are polishing compositions for removal of Co, for example, selectively over Cu, and methods of their use. A polishing composition comprising an abrasive and one or more Co complexors, where the polishing composition has a pH of 9 or more, and the Co complexor comprises one or more of functional groups selected from phosphonic acid (—P(═O)(OH) | 2014-08-28 |
20140243251 | PROCESS FOR PRODUCING GRANULES COMPRISING ONE OR MORE COMPLEXING AGENT SALTS - A process for producing granules comprising one or more complexing agent salts of formula (I): | 2014-08-28 |
20140243252 | LAUNDRY DETERGENT FORMULATION - An improved binder for use in making laundry detergent compositions, more specifically bleach activator granules, is described. The binder utilizes glycerin as a replacement for fatty acids in the overall granule mixture which improves solubility and reduces odor. | 2014-08-28 |
20140243253 | STRUCTURED DETERGENT OR CLEANING AGENT HAVING A FLOW LIMIT - The invention describes a stable liquid washing agent or liquid cleaning agent having a yield point and very good dispersing properties. The agents contain anionic and nonionic surfactants as well as inorganic salt, at a specific ratio to one another. The invention also relates to use of the liquid washing agent or liquid cleaning agent, and to a method for manufacturing it. | 2014-08-28 |
20140243254 | Polymeric Hyperbranched Carrier-Linked Prodrugs - The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein POL is a polymeric moiety, each Hyp is independently a hyperbranched moiety, each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs and methods of treatment. | 2014-08-28 |
20140243255 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS - The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1. | 2014-08-28 |
20140243256 | ARENAVIRUS INHIBITING PEPTIDES AND USES THEREFOR - The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15). | 2014-08-28 |
20140243257 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula I: | 2014-08-28 |
20140243258 | METHODS AND COMPOSITIONS FOR TARGETING ADIPOSE CELLS IN MAMMALS - Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo. | 2014-08-28 |
20140243259 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF - The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α | 2014-08-28 |
20140243260 | CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE - The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder. This method includes selecting a subject suffering from the disorder and administering to the subject a therapeutically effective amount of a chimeric protein according to the present invention. | 2014-08-28 |
20140243261 | Method for treating diabetes and fatty liver disese by stimulating cellular metabolism - The present invention is a method of treating various diseases and conditions through administering a substantial caloric load coupled with administration of hormone to stimulate the body to convert that caloric load and increase metabolism in at least some cells. Body functioning converts intracellular adenosine triphosphate (ATP) as a part of normal cell function. Complex control systems balance caloric inputs by managing internal hormone levels to consume, store, or eliminate various types of caloric inputs. This invention stimulates these systems to increase metabolism of cells within the body and thereby treat various diseases and conditions. Many patients find their metabolism after treatment to be in better balance, and the patient's health improved. | 2014-08-28 |
20140243262 | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 2014-08-28 |
20140243263 | METHOD OF ENHANCING DIABETES RESOLUTION - Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient. | 2014-08-28 |
20140243264 | METHODS OF TREATMENT FOR RETINAL DISEASES - The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF. | 2014-08-28 |
20140243265 | ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES - High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples. | 2014-08-28 |
20140243266 | USES AND METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES - The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders. | 2014-08-28 |
20140243267 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES - The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers. | 2014-08-28 |
20140243268 | ERBB2 Peptides - Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length. | 2014-08-28 |
20140243269 | METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS - Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication for effecting neuroprotection in a subject suffering from schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis (MS), Amylotrophic Lateral Sclerosis (ALS), stroke, traumatic brain injury, and/or spinal cord injury. | 2014-08-28 |
20140243270 | PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS - A pharmaceutical composition containing a soluble Neuregulin-1 isoform representing Posttranslational Neuregulin-1 modifications. | 2014-08-28 |
20140243271 | THERAPEUTIC AGENT FOR RHINITIS - The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects.
| 2014-08-28 |
20140243272 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE - An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man. | 2014-08-28 |
20140243273 | METHODS FOR TREATING INFLAMMATORY DISEASES AND PHARMACEUTICAL COMBINATIONS USEFUL THEREFOR - The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a compound of Formula I and an optional co-therapy (e.g., chemotherapy agent, DMARD, or any combination thereof). The present invention also provides a pharmaceutical composition comprising a compound of Formula I, a method of manufacturing a pharmaceutical composition comprising a compound of Formula I, and a method of administering a pharmaceutical composition comprising a solid form of a compound of Formula I. | 2014-08-28 |
20140243274 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION - Compounds of formula R | 2014-08-28 |
20140243275 | Galectin-3C Combination Therapy for Human Cancer - The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses. | 2014-08-28 |
20140243276 | SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER) - A method of using a Smac mimetic and pharmaceutical compositions thereof. | 2014-08-28 |
20140243277 | Water Soluble Membrane Proteins and Methods for the Preparation and Use Thereof - The present invention is directed to water-soluble membrane proteins, methods for the preparation thereof and methods of use thereof. | 2014-08-28 |
20140243278 | Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof - Disclosed is an acid addition salt of donepezil, wherein acid counterion is selected from the group consisting of pamoic acid, cypionic acid, camphor sulfonic acid, enanthic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, valeric acid, Dibenzoyl-D-Tartaric acid and terephthalic acid. Disclosed is a process for the preparation and pharmaceutical composition comprising the same. More specifically, disclosed is concerned with the pamoate acid addition salts of donepezil. Disclosed also is long acting formulation comprising the acid addition salt of donepezil and process for the preparation thereof. | 2014-08-28 |
20140243279 | METHODS AND COMPOSITIONS COMPRISING RIFABUTIN, CLARITHROMYCIN, AND CLOFAZIMINE - A composition of the present invention comprises an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, wherein the effective amount of the absorption enhancer is sufficient so that, when the composition is administered to a patient, an overall metabolism of clarithromycin as caused by rifabutin is reduced by shifting competing metabolism of rifabutin and clarithromycin so as to result in more active clarithromycin. | 2014-08-28 |
20140243280 | Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable Thereby - The invention relates to drug development and synthetic chemistry, in particular to the manufacture of biologically active compounds based on naturally occurring molecules. It also relates to novel biologically active compounds, for example aminoglycoside antibiotics, in a substantially pure regioisomeric form. | 2014-08-28 |
20140243281 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES - Provided herein are pediatric dosage forms for use in the treatment of a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of the pediatric dosage form comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are said pediatric dosage form for use in the treatment of a pediatric liver disease, for use in decreasing the levels of serum bile acids or hepatic bile acids, for use in the treatment of pruritis, for use in reducing liver enzymes or bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof. | 2014-08-28 |
20140243282 | METHODS AND COMPOSITIONS FOR DESIGNING NOVEL CONJUGATE THERAPEUTICS - The present invention relates to novel drug conjugates, where in two drugs are linked together through an appropriate linker having at least two functional groups capable of forming covalent bond with drugs D1 and D2. The invention also relates to developing novel compositions, methods for their preparation and their use in treating various disease conditions. | 2014-08-28 |
20140243283 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS - The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: | 2014-08-28 |
20140243284 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II), wherein R | 2014-08-28 |
20140243285 | LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USE THEREOF - The invention provides compositions comprising lipid-conjugated forms of capsular polysaccharide A (PSA) from | 2014-08-28 |
20140243286 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME - Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins. | 2014-08-28 |
20140243287 | PYRAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to pyrazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-08-28 |
20140243288 | FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS - The present invention relates to a fused ring-containing oxazolidinone compound shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof, wherein R | 2014-08-28 |
20140243289 | PRODRUGS OF MODULATORS OF ABC TRANSPORTERS - The present invention relates to prodrugs of modulators of ABC transporters, particularly, CFTR modulators, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2014-08-28 |
20140243290 | Aminopyrimidines as SYK Inhibitors - The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis. | 2014-08-28 |
20140243291 | METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME - The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof. | 2014-08-28 |
20140243292 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, | 2014-08-28 |
20140243293 | PHOSPHAPLATINS AS NEUROPROTECTIVE AGENTS - The present disclosure provides for compositions for the treatment of neurodegenerative diseases comprising one or more isolated phosphate complexes of platinum and methods of uses thereof for treating neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's disease, stroke, epilepsy, Parkinsons, Huntington's disease and diabetes associated peripheral neuropathy The present disclosure is also directed towards an anti-angiogenic composition useful for inhibiting angiogenesis related to age-related macular degeneration, diabetic retinopathy and tumor-associated angiogenesis. An embodiment of the present disclosure is also directed towards a method for modulating the expression of Pigment Epithelial Derived Factor (PEDF) gene in an individual in need thereof. The present disclosure also provides for a method of reducing neurotoxicity associated with the administration of a cancer therapy in a subject in need thereof comprising administering to the individual in need thereof a therapeutically effective amount of at least one or more isolated monomeric phosphate complexes of platinum described herein. | 2014-08-28 |
20140243294 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES - The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject. | 2014-08-28 |
20140243295 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES - The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and —a method of determining the level of a component of one or more of Bcl expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN. | 2014-08-28 |
20140243296 | Organic Compounds - A treatment regimen and dosage form comprising ritonavir and darunavir and their use in the treatment of HIV infection. | 2014-08-28 |
20140243297 | PETROLEUM JELLY-FREE UNGUENT COMPOSITIONS COMPRISING VITAMIN D COMPOUNDS AND OPTIONALLY STEROIDAL ANTI-INFLAMMATORY AGENTS - Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents. | 2014-08-28 |
20140243298 | C-3 ALKYL AND ALKENYL MODIFIED BETULINIC ACID DERIVATIVES - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: | 2014-08-28 |
20140243299 | Topical Formulations of Corticosteroids with Enhanced Bioavailability - Described herein are methods and compositions for increasing the bioavailability of a corticosteroid, such as hydrocortisone 17-butyrate, in a topical formulation. | 2014-08-28 |
20140243300 | Controlling the Bioavailability of Active Ingredients in Topical Formulations - Described are methods and compositions for tuning the bioavailability of an active agent, such as a corticosteroid, in a topical formulation. | 2014-08-28 |
20140243301 | CHLOROBIS COPPER (I) COMPLEX COMPOSITIONS AND METHODS OF MANUFACTURE AND USE - A method of manufacturing an anhydrous copper complex of formula C | 2014-08-28 |